Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with concurrent chemoradiotherapy and adjuvant camrelizumab for locally advanced head and neck squamous cell carcinoma
ChiCTR2200056298Phase 4Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2200056298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056298.